Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712244 | 1.00 | AMY1A (0.46) | AMY1AMAPTHTR2AALDH1A1NFE2L2 | |
| SCHEMBL14830711 | 0.98 | AMY1A (0.45) | AMY1AMAPTHTR2AALDH1A1NFE2L2 | |
| SCHEMBL22505897 | 0.85 | FFAR1 (0.38) | AMY1AMAPTHTR2AALDH1A1NFE2L2 | |
| SCHEMBL23259236 | 0.84 | KDM4E (0.40) | AMY1AMAPTALDH1A1NFE2L2FFAR1 | |
| SCHEMBL504965 | 0.82 | ALDH1A1 (0.52) | AMY1AMAPTHTR2AALDH1A1NFE2L2 | |
| SCHEMBL14482753 | 0.82 | ALDH1A1 (0.52) | AMY1AMAPTHTR2AALDH1A1NFE2L2 | |
| SCHEMBL29849146 | 0.82 | ALDH1A1 (0.52) | AMY1AMAPTHTR2AALDH1A1NFE2L2 | |
| SCHEMBL3823791 | 0.80 | MAPT (0.50) | AMY1AMAPTHTR2AALDH1A1NFE2L2 | |
| SCHEMBL19198177 | 0.79 | NFE2L2 (0.72) | NFE2L2 | |
| SCHEMBL15202541 | 0.79 | FYN (0.51) | MAPTALDH1A1MEN1KMT2APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810571-A | Inorganic nano material prints ink and its preparation method and application | TCL集团股份有限公司 | 2019-05-28 | — | — | CN | claimed |
| CN-106083536-B | A kind of preparation method of Ansai Qu key intermediate | 浙江永太科技股份有限公司 | 2018-10-30 | — | — | CN | claimed |
| CN-106083536-A | A kind of preparation method of the bent key intermediate in Ansai | 浙江永太科技股份有限公司 | 2016-11-09 | — | — | CN | claimed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4466266-B1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | TRANSNEURAL THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260070927-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| EP-0193055-B1 | ANTITUMORALS(1,2-DIPHENYL-ETHYLENE DIAMINE)-PLATINUM (II) COMPLEXES | ASTA Pharma AG (DE) | 1990-05-16 | — | — | EP | disclosed |
| US-4730068-A | SPECIAL EFFECT ON BREAST CANCER | ASTA-WERKE AKTIENGESELLSCHAFT (DE) | 1988-03-08 | — | — | US | disclosed |
| CN-86100815-A | The preparation method who suppresses (1, the 2-diphenyl ethylene diamine)-platinum (II) complex compound of tumour | — | 1986-11-26 | — | — | CN | disclosed |
| EP-0193055-A1 | Antitumorals(1,2-diphenyl-ethylene diamine)-platinum (II) complexes | ASTA Pharma AG (DE) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | AMY1A 1206/4885MAPT 2629/4885HTR2A 678/4885 |
| US-20260070927-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | MALT1, CCR1, CCR6 | AMY1A 641/4885MAPT 4693/4885HTR2A 3728/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | AMY1A 4858/4885MAPT 2501/4885HTR2A 3888/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | AMY1A 4151/4885MAPT 2305/4885HTR2A 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.